NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS
In March 2019, Madrigal Pharmaceuticals, Inc. announced that it has initiated its Phase 3 trial in non-alcoholic steatohepatitis (NASH) with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world.
In March 2019, Genfit started trading on NASDAQ, and issued new shares in its existing Euronext Paris listing. The company raised a total of EUR 120 million (about US$ 135 million).
In February 2019, Intercept Pharmaceuticals, Inc. announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis owing to non-alcoholic steatohepatitis (NASH).
In October 2018, Novartis entered into a clinical development agreement with Pfizer, which will include a study combining tropifexor and one/more Pfizer compounds for the treatment of NASH.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 